GNRH1 and ovarian hyperstimulation syndrome: In the BEYOND trial, OHSS incidence in the GnRH antagonist group may have been lower if a GnRH agonist trigger had been allowed; however, it would have confounded the interpretation of any potential differences in ovarian response among the two groups.